30

Enwei Pharmaceutical Co. Ltd. A

301331 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

23.98CNY+0.19 (+0.80%)

Price History

Full chart

Market Stats

Previous Close23.79
Open23.78
Day Range23.28 – 24.25
52-Week Range18.87 – 32.68
Volume4.46M
Market Cap2.25B
P/E (TTM)78.00
Forward P/E0.00
EPS0.28
Dividend Yield4.72%
Beta0.58
50-Day Avg21.30
200-Day Avg25.06

About

Enwei Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of Chinese medicines and chemical drugs in China. The company offers drugs in the areas of gynecology, pediatrics, respiratory, stomatology, digestive, cardiovascular, hepatobiliary, and dermatology under the Jieeryin, Haowayou, and Likeshu brands. It also provides products for cold and fever relief, dental care, warming/nourishing/tonic purposes, and other uses; ointments, suppositories, capsules, effervescent tablets, and antibacterial washes; hygiene products, disinfectants, medical devices, pharmaceutical packaging materials and containers, and daily chemical products; compound preparations, oral liquids and solutions, syrups, and decoctions; and tablets, granules, powders, large honey and water pills, water-honey and concentrated pills, wax pills, and syrups. In addition, the company engages in medical research and experimental development. Enwei Pharmaceutical Co., Ltd. was founded in 1986 and is based in Chengdu, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Yongjiang Xue
  • Employees1.50K
  • HeadquartersNo. 458, Shuanghua Road, Chengdu, China, 610200, China
  • Websitehttps://www.enwei.com.cn

Leadership

  • Mr. Yongjiang XueChairman & CEO · b. 1971
  • Mr. Xue GangVice Chairman & President · b. 1973
  • Mr. Dawei HuCFO, VP & Secretary of the Board · b. 1987
  • Mr. Zhuang YanVP & Director · b. 1961
  • Mr. Lei ChenVice President · b. 1976
  • Hui NingAccounting Supervisor

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue620.67M634.16M679.70M691.57M785.19M812.13M900.77M
Growth (%)-+2.17%+7.18%+1.75%+13.54%+3.43%+10.91%
Cost of Revenue214.60M269.76M296.74M344.43M382.74M399.44M454.78M
Gross Profit406.07M364.40M382.95M347.15M402.45M412.68M445.99M
Gross Margin65.42%57.46%56.34%50.20%51.26%50.82%49.51%
Operating Expense290.22M238.81M262.54M265.53M310.25M362.12M384.86M
Operating Income115.85M125.59M120.41M81.62M92.20M50.57M61.13M
Operating Margin18.66%19.80%17.72%11.80%11.74%6.23%6.79%
EBITDA267.44M238.24M183.65M112.92M136.16M95.78M114.54M
EBITDA Margin43.09%37.57%27.02%16.33%17.34%11.79%12.72%
Net Income82.59M98.74M101.73M67.80M86.31M37.50M51.94M
Net Income Margin13.31%15.57%14.97%9.80%10.99%4.62%5.77%
R&D4.40M4.84M4.32M7.52M16.82M9.07M5.52M
R&D as % of Total Revenue0.71%0.76%0.64%1.09%2.14%1.12%0.61%
Interest Expense16.29M1.41M917.40K147.74K11.91K2.61M2.56M
Interest Expense % of Total Revenue2.62%0.22%0.13%0.02%0.00%0.32%0.28%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets748.49M848.86M869.09M1.41B1.34B1.50B1.55B
Total Liabilities263.66M262.34M226.84M253.08M234.31M446.86M477.86M
Total Equity405.09M586.52M642.25M1.15B1.10B1.06B1.07B
Cash47.41M63.02M64.25M341.58M236.12M370.27M362.31M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow119.70M78.52M87.58M62.35M84.01M78.92M109.59M
Capital Expenditure21.24M31.16M38.21M23.56M134.05M50.23M56.38M
Free Cash Flow98.46M47.36M49.36M38.80M-50.04M28.69M53.21M
Dividends Paid81.31M1.58M46.00M-112.22M56.96M20.78M
FCF to OCF82.26%60.31%56.37%62.22%-59.56%36.35%48.56%
Dividend Paid to FCF82.57%3.33%93.19%--224.27%198.55%39.04%

Earnings

Report DateSep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------
EPS Actual0.100.180.270.350.090.140.080.120.040.150.160.22-0.020.140.120.03
Surprise----------------
Timing----------------

Key Statistics & Ratios

Market Cap2.25B
Enterprise Value1.98B
Trailing P/E78.00
Forward P/E0.00
Price / Sales2.72
Price / Book2.20
EPS0.28
Book Value10.03
Revenue (TTM)826.13M
Gross Profit (TTM)416.86M
EBITDA76.54M
Profit Margin3.59%
Operating Margin0.05%
Return on Equity2.82%
Return on Assets1.24%
Shares Outstanding102.89M
Shares Float30.87M
Beta0.58
Dividend Yield4.72%
Dividend Rate1.03
Payout Ratio3.73%

Dividends

20262×
0.68May 28, 20260.35Jan 8, 2026
20251×
0.18May 28, 2025
20241×
0.80May 23, 2024
20231×
1.08May 23, 2023

Stock Splits

  • May 23, 20241.48:1